Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ltd V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Comment by JohnnyTSXon Apr 16, 2018 5:32pm
184 Views
Post# 27893843

RE:Terms

RE:TermsUnless I am missing something, my perspective is similar:

1) If you wait until the deal closes, you will get 90c/share (in cash or DSKE shares, your choice) AND a "free ride" to the bonus payout TBD ~12 months in the future.

2) If you sell prior to the deal closing, you don't get the "free ride".

3) The "free ride" could be 45c per share or 0c per share or anything in between based on EBITDA over $18M CAD and the predetermined calculation thereof (I still need to do some homework on this piece - i.e. how much over $18M EBITDA to trigger the whole $0.45c/share? - if anyone has already done the math, I would be forever grateful if it could be shared).

4) If you add to your position at say 95c today, you are paying a 5c premium for that "free ride" and so on.  Not sure where the market will price the risk/return, but I think it would be at or near current levels.  Maybe a $1/share maximum - but who knows?

5) Folks who bought at ~90c today were smart.  They did not pay the premium for the "free ride" and have nothing to lose holding until deal closing. 

6) The decision will be when mid June (deal close) nears, you will have to decide whether to take the premium now, or wait to see what a year brings - if you think the EBITDA calculation will net you more than the premium then it might be a wise investment.

All in all it is somewhat an excercise in discipline, greed, and risk tolerance.  Good luck everyone!

John.


<< Previous
Bullboard Posts
Next >>